Cargando…
Optimal management of atypical hemolytic uremic disease: challenges and solutions
Atypical hemolytic uremic syndrome (aHUS) is a chronic life threatening condition that arises from genetic abnormalities resulting in uncontrolled complement amplifying activity. The introduction of eculizumab, the humanized monoclonal antibody, has brought about a paradigm shift in the management o...
Autores principales: | Raina, Rupesh, Grewal, Manpreet K, Radhakrishnan, Yeshwanter, Tatineni, Vineeth, DeCoy, Meredith, Burke, Linda LG, Bagga, Arvind |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732511/ https://www.ncbi.nlm.nih.gov/pubmed/31564951 http://dx.doi.org/10.2147/IJNRD.S215370 |
Ejemplares similares
-
Anti-factor H antibody and its role in atypical hemolytic uremic syndrome
por: Raina, Rupesh, et al.
Publicado: (2022) -
Pediatric Atypical Hemolytic Uremic Syndrome Advances
por: Raina, Rupesh, et al.
Publicado: (2021) -
Atypical Hemolytic-Uremic Syndrome: Genetic Basis, Clinical Manifestations, and a Multidisciplinary Approach to Management
por: Yerigeri, Keval, et al.
Publicado: (2023) -
Effect of Immunosuppressive Therapy on the Occurrence of Atypical Hemolytic Uremic Syndrome in Renal Transplant Recipients
por: Raina, Rupesh, et al.
Publicado: (2018) -
Atypical hemolytic uremic syndrome
por: Loirat, Chantal, et al.
Publicado: (2011)